Cite
HARVARD Citation
Shah, H. et al. (2022). Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents. Leukemia & lymphoma. 63 (4), pp. 813-820. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Shah, H. et al. (2022). Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents. Leukemia & lymphoma. 63 (4), pp. 813-820. [Online].